An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:2/2/2019
Start Date:November 29, 2016
End Date:December 16, 2022
Contact:Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:
Email:Clinical.Trials@bms.com

Use our guide to learn which trials are right for you!

Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors

The purpose of this study is to evaluate the safety and effectiveness of experimental
medication BMS-986207 by itself and in combination with Nivolumab in solid cancers that are
advanced or have spread.


For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Women and men ≥18 years of age with Eastern Cooperative Oncology Group (ECOG)
performance status of 0 or 1

- Must have received and progressed on or failed one standard/approved treatment for
cancer type, if available

- At least 4 weeks since any previous treatment for cancer

- Subject must consent to pretreatment and on treatment tumor biopsies

- At least one lesion with measurable disease at baseline

- Adequate organ and marrow function

Exclusion Criteria:

- Patients with primary brain tumors or primary tumors with central nervous system
metastases as only location of disease. Controlled brain metastases are permitted

- Prior organ transplant

- Participants with second/other active cancers requiring current treatment

- Uncontrolled/significant heart disease

- History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or
Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency
Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)

- Active/uncontrolled autoimmune disease

- Active infection

Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
7
sites
Pittsburgh, Pennsylvania 15232
Phone: 412-623-5396
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
92 2nd St
Hackensack, New Jersey 07601
(201) 996-5900
Phone: 551-996-8598
John Theurer Cancer Center at the Hackensack University Medical Center The mission of the John...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Nedlands, Western Australia 6009
?
mi
from
Nedlands,
Click here to add this to my saved trials
New York, New York 10032
Phone: 212-305-0983
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
Phone: 215-214-3773
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
3451 Walnut St
Philadelphia, Pennsylvania 19104
1 (215) 898-5000
Univ of Pennsylvania Penn has a long and proud tradition of intellectual rigor and pursuit...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Salt Lake City, Utah 84112
Phone: 801-587-5559
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials